Participated · Series A · Apr 2026

Xellar Biosystems develops a closed-loop platform that integrates human organ-on-chip models, automated experimentation, high-content imaging, multi-omics analysis, and machine learning to generate high-quality, human-relevant biological data. The company aims to produce multi-dimensional datasets under physiologically relevant conditions to enable biological foundation models and virtual cell systems for prediction of mechanism of action, toxicity, disease progression, and therapeutic response. Xellar positions its approach as an alternative to traditional preclinical models that rely on animals or simplified in vitro assays. With the $50 million Series A/A+ financing, Xellar plans to scale automated biological data generation, expand computational and AI teams, and accelerate virtual cell technology development. The company presents this platform as a way to make drug discovery faster, more predictive, and more scalable. Xellar was founded in 2022.

Led · Series A · Mar 2026

Founded in 2021 by EPFL Professor Li Tang and XtalPi Technology, Shenzhen-based Leman Biotech focuses on developing, producing, and commercializing metabolic-enhanced immune cell therapies. Its lead program is an extremely low-dose, metabolism-boosted CAR-T cell drug that is heading into a registration Phase I clinical trial. The company is also advancing metabolic-enhanced therapies for solid tumors and is building automated manufacturing processes to scale production. Leman’s core immunometabolism platform is protected by multiple PCT and Chinese invention patents, and the team’s research has appeared in Nature, Nature Biotechnology, Nature Immunology, and The Lancet Haematology. While still pre-revenue, the firm has attracted repeated backing from strategic and financial investors who view its first-in-class technology as globally differentiated.

Participated · Series A · Jan 2026

Founded at the end of 2020 in Shenzhen, Signet Therapeutics has built a proprietary organoid disease-modeling and AI-driven drug discovery platform aimed at solving unmet needs in diffuse gastric cancer, liver cancer, lung cancer and other metastatic solid tumors. Its lead asset, SIGX1094, is positioned as the world’s first targeted drug for diffuse gastric cancer; it holds both FDA and NMPA INDs, FDA Orphan Drug and Fast Track designations, and is currently in a Phase I study at Peking University Cancer Hospital while funds are earmarked to launch a global Phase II trial. The second pipeline, SIGX2649, is a pan-TEAD inhibitor targeting the Hippo pathway and is preparing for simultaneous China-U.S. IND filings and a Phase I initiation. Overall, the company is advancing four first-in-class programs and continues to expand its organoid platform to support internal and partnered drug discovery. The founding team hails from Harvard, MIT, Dana-Farber and other top institutions, and has published over 20 high-impact papers in Nature, Nature Medicine and Cancer Cell. To date, Signet Therapeutics has secured approximately RMB 300 million in funding and grants and holds more than 40 core patents, underlining a solid financial and intellectual-property foundation for future growth.

Participated · Equity · Sep 2025

GoFintech Innovation is focused on a platform to convert real-world assets into digital tokens, targeting sectors like real estate and commodities. The company revised a prior fundraising plan and completed a private placing instead, collecting nearly HK$1.33 billion. It placed 745 million shares at HK$1.78 each, representing a little more than 8% of the company’s share capital. Inkeverse Group committed HK$300 million for a meaningful stake, and existing shareholder XtalPi acquired an additional 22 million shares. Most other investors remained undisclosed, indicating strong private interest. The proceeds are earmarked to accelerate development and deployment of its asset-tokenization platform. Shares of GoFintech Innovation, Inkeverse Group, and XtalPi rose in Hong Kong trading after the announcement.

Participated · Series A · Jul 2024

ReviR Therapeutics develops small-molecule RNA-targeting therapies using an AI-driven discovery approach. The company leverages its VoyageR platform to discover and optimize chemical matter against RNA targets, including splice modulation technologies. Its initial therapeutic focus includes Huntington’s disease, Charcot‑Marie‑Tooth disease, amyotrophic lateral sclerosis, and other neurological and rare genetic disorders with limited treatment options. ReviR plans to further augment the VoyageR platform and advance proprietary programs toward clinical development. The company is led by CEO Dr. Peng Yue and was founded in 2021 in Brisbane, CA. Financially, ReviR closed a $30M Series A in the reported round, bringing total capital raised to $54M.